

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence set forth in SEQ ID NO: 1;
 - (b) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 2; and
 - (c) a nucleotide sequence fully complementary to (a) or (b).
2. - 3. (Canceled)
4. (Previously presented) A vector comprising the nucleic acid of claim 1.
5. (Previously presented) An isolated recombinant host cell comprising the vector of claim 4.
6. (Previously presented) The host cell of claim 5 that is a eukaryotic cell.
7. (Previously presented) The host cell of claim 5 that is a prokaryotic cell.
8. (Previously presented) A process of producing a CD20/IgE-receptor like polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express a CD20/IgE-receptor like polypeptide encoded by the nucleic acid.
9. (Canceled)
10. (Previously presented) The process of claim 8, wherein the vector further comprises a heterologous promoter operatively linked to the nucleotide sequence encoding the CD20/IgE-receptor like polypeptide.
- 11-50. (Canceled)
51. (Previously presented) A composition comprising a nucleic acid of claim 1 and a pharmaceutically acceptable formulating agent.
52. (Previously presented) A composition of Claim 51 wherein said nucleic acid is contained in a viral vector.

53. (Previously presented) A viral vector comprising a nucleic acid of claim 1.
54. (Previously presented) A fusion polypeptide comprising an amino acid sequence encoded by the nucleic acid sequence of claim 1 fused to a heterologous amino acid sequence.
55. (Previously presented) The fusion polypeptide of claim 54 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.
- 56-69. (Canceled)
70. (Previously presented) A nucleic acid according to claim 1 attached to a solid support.
71. (Canceled)
72. (Previously presented) The process of claim 8 further comprising isolating the polypeptide from the culture.